The user facility reported to terumo cardiovascular that during cardiopulmonary bypass, the vent valve, that was being used in the aortic root vent, leaked blood.Another valve was obtained from another pack and that valve also leaked.There was a delay of 5 minutes or less.The product was changed out.Procedure was completed successfully.There was a negligible amount of blood loss.
|
This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular systems in the initial report submitted to the fda on october 19, 2021.Upon further investigation of the reported event, the following information is new and/or changed: h6: (identification of evaluation codes 10, 11, 3331, 213, 67).Type of investigation #1: 10 - testing of actual/suspected device.Type of investigation #2: 11 - testing of device from same lot/batch retained by manufacturer.Type of investigation #3: 3331 - analysis of production records.Investigation findings: 213 - no device problem found.Investigation conclusions: 67 - no problem detected.The affected samples were returned and visually inspected with no anomalies noted.Ops valves are subject to a 100% leak test, which includes five different tests the units are run through to ensure there are no leaks and both the umbrellas and duckbills are functioning properly.The returned samples were leak tested and found to function as intended, and met all the product specifications.A retention sample was visually inspected with no anomalies noted.It was also leak tested and found to function as intended, and met all the product specifications.All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|